Uterine cervical dysplasia
Drug research and approvals for uterine cervical dysplasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 45 studies of uterine cervical dysplasia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 45
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNCT07925307 · Not applicable · University of California, San Diego · starts Oct 16, 2026
- Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living…NCT07645352 · Not applicable · Fred Hutchinson Cancer Center · starts Oct 15, 2026
- Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in…NCT07645378 · Not applicable · Fred Hutchinson Cancer Center · starts Oct 15, 2026
- C2001P-CS3: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNCT07576842 · Not applicable · University of California, San Diego · starts Nov 9, 2026
- Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical…NCT07572396 · Phase 2 · Amplexd Therapeutics, Inc. · starts Apr 30, 2026
- Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical CancerNCT07480902 · Not applicable · Timser SAPI de CV · starts Feb 3, 2026
- Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV…NCT07468695 · Not applicable · Fred Hutchinson Cancer Center · starts Oct 12, 2026
- Point of Care - Triage and Treatment for Cervical Pre-cancerNCT07461818 · Not applicable · Basic Health International, Inc. · starts Jan 1, 2026
- PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical DysplasiaNCT07454915 · Phase 2 · PapiVax Biotech, Inc. · starts Apr 1, 2026
Phase 3 4
- ImiquimodToll-like receptor 7 agonist
- LidocaineSodium channel alpha subunit blocker
- IsotretinoinRetinoic acid receptor agonist
- FluorouracilThymidylate synthase inhibitor
Phase 2 9
- CelecoxibCyclooxygenase-2 inhibitor
- CidofovirHuman herpesvirus 1 DNA polymerase inhibitor
- PaclitaxelTubulin inhibitor
- ProgesteroneProgesterone receptor agonist
- NelfinavirHuman immunodeficiency virus type 1 protease inhibitor
- Verpasep caltespenChaperonin GroEL 2 vaccine antigen
- Hexaminolevulinate
- Sivifene
- Tipapkinogene sovacivec
Phase 1 or earlier 3
- Methyl aminolevulinateDNA inhibitor
- TerameprocolDNA inhibitor
- Curcumin
How its trials ended
335 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 62 whose ending is known, 48% met their primary endpoint, 16% missed it and 35% stopped early.
- Completed, result not reported14242%
- Ongoing7322%
- Status unknown5817%
- Met its primary endpoint309%
- Missed its primary endpoint103%
- Stopped: other or unclear103%
- Stopped: enrollment or feasibility82%
- Stopped: funding31%
- Stopped: sponsor or business decision1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA